PeptideStack
5.2kquestions
20kanswers
220users

What happens to ecnoglutide after four weeks at 2–8 °C in solution?

Asked 7 Jul 2025Modified 10 months agoViewed 11k times
9

The case in front of me: ecnoglutide · four weeks · 2–8 °C.

I want to know whether this is a real physical effect or an artefact of how it is measured.

What prompted the question is an inconsistency between two sources I otherwise trust.

Is the standard explanation correct, and if so, what is the evidence for it?

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

701 questions
shelf-life
shelf-life

How long a preparation remains within specification: labelled expiry for a sealed lyophilised vial, beyond-use dating after reconstitution, and…

327 questions
ecnoglutide
ecnoglutide

A long-acting GLP-1 receptor agonist with a cAMP-biased signalling profile. A niche tag, mostly used for mechanism questions about biased agonism…

223 questions
shareeditfollowflag
RM
askedrosa_mendieta8k167 Jul 2025
7How many freeze-thaw cycles are we talking about? One and ten are different questions. – meniscus_film 3 months ago
6Add the diluent — a preservative changes the in-use period entirely. – RP_C18 2 months ago
add a comment

5 Answers

Accepted answer first, then by votes
69

Accepted answer

four weeks is 28 days, which at 2–8 °C is on the order of 28 refrigerated days. 2–8 °C is the condition the rule of thumb is anchored to, so it is the baseline rather than a multiplier: everything else in this thread is quoted relative to it. In solution the routes that matter are hydrolysis of the backbone, deamidation at Asn, and physical association — the first two cost content, the third costs neither until it precipitates. Over 28 days at 2–8 °C you should expect all three to have moved, and a purity figure to have noticed only some of them. Reconstituted material has no certificate; the one in the box describes the powder.

Start with the sequence, because which pathways are available depends on which residues are present.

Oxidation targets methionine, cysteine and tryptophan, adding sixteen daltons per oxygen. It is catalysed by trace metals and promoted by dissolved oxygen and by light.

Aggregation is physical: peptides unfold at air-liquid interfaces and associate. Shaking maximises that interface, which is why swirling and shaking produce visibly different outcomes on the same vial.

Metal-catalysed oxidation of methionine is documented across peptide and protein formulations and is why chelators appear in some formulations.

Sequence determines which pathways apply, so general statements are general.

Swirl, never shake. Aggregation is a handling problem more than a time problem.

shareimprove this answerflag
SG
answered · acceptedsinead_gaffney28k3728 Aug 2025
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
26

The relevant point is that a mass shift of plus one dalton is deamidation and plus sixteen is oxidation, so degradation is often visible in a mass spectrum if anyone looks.

Hydrolysis cleaves the backbone, most readily at aspartate-proline and aspartate-glycine sequences, and is acid-catalysed. In a dry solid it barely proceeds at all.

A mass spectrum resolves most of this: minus eighteen is dehydration or succinimide, plus one is deamidation, plus sixteen is oxidation, and an unchanged mass with a shifted retention time is an isomer.

A mass spectrum names the pathway. Plus one, plus sixteen, minus eighteen.

shareimprove this answerflag
TV
answeredten_mg_vial31k1388 Sept 2025
19

Answering this needs the physical state, since a dry powder is protected from most of these and a solution is protected from none.

Freeze-thaw cycling drives aggregation through concentration at the ice interface and pH shifts as buffer components crystallise out at different rates. Each cycle costs something.

Deamidation converts asparagine or glutamine to the corresponding acid via a succinimide intermediate, adding one dalton. It is base-catalysed, accelerates above neutral pH and is the dominant aqueous pathway for many peptides.

Sequence decides which pathways are even available. Check the residues.

shareimprove this answerflag
NN
answerednine_point_nine60k1486 Aug 2025
I would add a sentence about light, since tryptophan-containing sequences care. – Dr_Priya_Raghunathan 6 months ago
The doubling-per-ten-degrees rule is the part I did not know and now use constantly. – Dr_Idris_Coulibaly 5 months ago
add a comment
15

Asparagine and glutamine are the deamidation risk, and methionine is the oxidation risk.

Light exposure matters for tryptophan-containing sequences and for anything with a chromophore. Amber vials and a closed box are free mitigations.

At dilute concentrations, suspect adsorption before you suspect chemistry.

shareimprove this answerflag
P9
answeredplate_count_9k78k24817 Aug 2025
12

This is answerable from the chemistry rather than from anecdote, which is unusual and welcome.

Adsorption onto glass and plastic is significant at low concentrations — micrograms per millilitre — and negligible at milligrams per millilitre. It is the usual explanation for an apparent loss in a dilute preparation.

Deamidation via the succinimide intermediate is well characterised, with sequence-dependent rates highest for asparagine-glycine motifs.

Apparent loss in a dilute preparation is usually adsorption rather than degradation and is worth ruling out first.

Cold, dry, dark, still. Those four words cover most of the mitigation.

shareimprove this answerflag
MO
answeredmarta_okonkwo190k25812 Oct 2025

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.